Muscarinic Agonist Program for Alzheimer’s Disease

Global R&D and commercialization agreement (2016) under which Abbvie, formerly known as Allergan, gains exclusive global rights to our broad portfolio of novel subtype-selective muscarinic receptor agonists in development for the treatment of major neurological diseases, including Alzheimer’s disease. We received $125 million upfront and are eligible to receive contingent milestone payments of up to approximately $3.25 billion, plus up to double-digit royalties on net sales of all products resulting from the partnership.

AbbVie has also committed up to $50 million to a R&D program to be conducted jointly by AbbVie and us, aimed at advancing multiple candidates through Phase 2 studies. AbbVie will be responsible for the development of licensed compounds upon initiation of Phase 2b studies and for subsequent manufacturing and commercialization of the products.

The agreement gives AbbVie exclusive rights to a broad clinical and preclinical portfolio of first-in-class selective small molecule agonists targeting muscarinic M1 and M4 receptors in the brain, including HTL009936, HTL0018318 and HTL0016878.

In 2017, we agreed with AbbVie to amend this agreement, providing us with a license to develop and promote HTL0018318 in Japan as a potential new treatment for patients with Dementia with Lewy Bodies (DLB). AbbVie has retained the right to develop HTL0018318 in DLB globally (outside Japan).

In 2020, Allergan was acquired by U.S. pharmaceutical company, AbbVie.


Immunology Program

Discovery collaboration and option to license agreement with AbbVie (2020) to discover, develop and commercialize novel medicines that modulate G protein-coupled receptor (GPCR) targets of interest to AbbVie. The collaboration will initially focus on discovery of novel small molecules targeting inflammatory and autoimmune diseases.

Sosei Heptares will apply its proprietary StaR® technology and GPCR-focused Structure-based Drug Design (SBDD) capabilities and fund R&D activities through the completion of Investigational New Drug (IND)-enabling studies. AbbVie may then pay license fees to exercise its exclusive license options and assume responsibility for global development and commercialization.

Under the terms of the agreement, Sosei Heptares is eligible to receive up to US$32 million in upfront and near-term milestone payments, as well as potential option, development and commercial milestones of up to $377 million, plus tiered royalties on global commercial sales.

AbbVie has the option to expand the collaboration up to a total of four targets.